Research programme: tenofovir monophosphonamidates - Gilead SciencesAlternative Names: Tenofovir monophosphonamidates research programme - Gilead Sciences
Latest Information Update: 22 Apr 2003
At a glance
- Originator Gilead Sciences
- Mechanism of Action RNA-directed DNA polymerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 21 Apr 2001 New profile
- 21 Apr 2001 Preclinical development for HIV infections treatment in USA (PO)